TGRX-678

N/A

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameTGRX-678
Drug Alias NameTGRX-678
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShenzhen TargetRx Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShenzhen TargetRx Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Chronic-PhaseLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A